Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-blind, Randomized, Placebo-controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
Brief Summary: This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 400 (267 AA4500 and 133 placebo) men will be randomized. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle.

Before dosing, subjects will be stratified by degree of penile curvature deformity (ie, 30º to 60º or 61º to 90º) and then randomized into two treatment groups to receive in a 2:1 ratio either AA4500 0.58 mg or placebo.

In this study, qualified subjects may receive up to four treatment cycles; each cycle will be separated by a period of 42 days (± 5 days). During each treatment cycle, subjects will receive two injections of study drug with at least 24 hours but not more than 72 hours between injections. After the final injection of each treatment cycle, the investigator or qualified designee will model the penile plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \<15 degrees after the first, second, or third cycle of injections or if further treatment is not clinically indicated, subsequent treatment cycles will not be administered.

Following the maximum of four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 169 (± 7 days), 232 (± 7 days), 295 (± 7 days), 365 (± 7 days) (nominal weeks 24, 33, 42 and 52). Subjects randomized to placebo may receive open-label AA4500 treatment after completing this study as part of another protocol.


Options:
A: Arm Label: AA4500; Type: EXPERIMENTAL; Interventions: Biological: AA4500 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: AA4500; Assigned to Arm(s): AA4500 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Experimental: Autologous PRP followed by Placebo Group; Type: EXPERIMENTAL; Interventions: Drug: Autologous Platelet Rich Plasma, Other: Saline Solution | Arm Label: Experimental: Placebo followed by Autologous PRP Group; Type: EXPERIMENTAL; Interventions: Drug: Autologous Platelet Rich Plasma, Other: Saline Solution | Intervention Type: DRUG; Name: Autologous Platelet Rich Plasma; Assigned to Arm(s): Experimental: Autologous PRP followed by Placebo Group, Experimental: Placebo followed by Autologous PRP Group | Intervention Type: OTHER; Name: Saline Solution; Assigned to Arm(s): Experimental: Autologous PRP followed by Placebo Group, Experimental: Placebo followed by Autologous PRP Group
C: Arm Label: Group 1 - Control; Type: SHAM_COMPARATOR; Interventions: Device: RestoreX PTT - open label phase only | Arm Label: Group 2 - PTT 1x daily x 3 months; Type: EXPERIMENTAL; Interventions: Device: RestoreX PTT - randomized and open label | Arm Label: Group 3 - PTT 2x daily x 3 months; Type: EXPERIMENTAL; Interventions: Device: RestoreX PTT - randomized and open label | Arm Label: Group 4 - PTT 3x daily x 3 months; Type: EXPERIMENTAL; Interventions: Device: RestoreX PTT - randomized and open label | Intervention Type: DEVICE; Name: RestoreX PTT - randomized and open label; Assigned to Arm(s): Group 2 - PTT 1x daily x 3 months, Group 3 - PTT 2x daily x 3 months, Group 4 - PTT 3x daily x 3 months | Intervention Type: DEVICE; Name: RestoreX PTT - open label phase only; Assigned to Arm(s): Group 1 - Control
D: Arm Label: AA4500; Type: EXPERIMENTAL; Interventions: Biological: AA4500 | Intervention Type: BIOLOGICAL; Name: AA4500; Assigned to Arm(s): AA4500

Answer: A